Company News »

Acceleron to Present New Dalantercept Clinical Data at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium

Business Wire
Share on StockTwits
Published on

Acceleron Pharma Inc. (NASDAQ:XLRN) , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma (RCC) will be presented at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium in Orlando, Florida. Dr. Martin H. Voss, medical oncologist at Memorial Sloan Kettering Cancer Center and lead investigator for the DART clinical trial, will present the data in an oral session on February 28, 2015. The DART study data will also be presented as a poster presentation during the meeting.

Details for the oral and poster presentations are provided below:

Oral Presentation Abstract 407

Title:

Preliminary Results from Part 1 of the DART Study: Dose Escalation and Expansion Cohorts of
Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Presenter: Martin H. Voss, M.D., Memorial Sloan Kettering Cancer Center
Session: Oral Abstract Session: Renal Cell Cancer
Date: Saturday, February 28
Time: 10:00 a.m. EST (Rosen Shingle Creek Hotel)

Poster Presentation Board B5

Title:

Preliminary Results from Part 1 of the DART Study: Dose Escalation and Expansion Cohorts of
Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Presenter: Martin H. Voss, M.D., Memorial Sloan Kettering Cancer Center
Session: General Poster Session C: Renal Cell Cancer
Date: Saturday, February 28
Times: 7:00-7:55 a.m. and 11:30-1:00 p.m. EST (Rosen Shingle Creek Hotel)

The poster and presentation slides will be available on Accelerons website (www.acceleronpharma.com) under the Publications section on February 28, 2015.

About the DART Phase 2 Clinical Trial in RCC

The phase 2 clinical trial is a two-part study in patients with advanced renal cell carcinoma. Part 1 is a dose-escalation study of dalantercept in combination with axitinib to evaluate the safety and tolerability of the combination in patients whose disease has progressed following one to three lines of prior therapy. Part 2 is a randomized, double-blind study of 130 patients with advanced renal cell carcinoma who have progressed following treatment with a VEGF receptor tyrosine kinase inhibitor. Patients may have also received prior mTOR therapy and/or immunotherapy. The objective of the study is to determine whether treatment with dalantercept in combination with axitinib prolongs progression-free survival compared to treatment with axitinib plus placebo. For additional information on this clinical trial, please visit www.clinicaltrials.gov, identifier NCT01727336.

About Dalantercept

Dalantercept (ACE-041) is an investigational protein therapeutic that inhibits angiogenesis by preventing BMP9, a protein in the TGF- superfamily, from interacting with activin receptor-like kinase 1 (ALK1), a cell-surface receptor found on proliferating vascular endothelial cells. Dalantercept inhibits ALK1 signaling, which is required for the development of mature, functional vasculature.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.

Share on StockTwits